Evidence map›Paper›PMID 26700033›Full record

ArticlePloS one2015

(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.

Eleni Gourni, Coline Canovas, Victor Goncalves, Franck Denat, Philipp T Meyer, Helmut R Maecke

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Towards Dual-Tracer SPECT for Prostate Cancer Imaging Using [Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Exploring the Therapeutic Potential ofInternational journal of molecular sciences · 2025
    Article
  5. Review
  6. Article
  7. Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  8. [European journal of nuclear medicine and molecular imaging · 2022
    Article
  9. Article
  10. Review
  11. EJNMMI research · 2021
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Performance ofEuropean journal of nuclear medicine and molecular imaging · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Eleni GourniGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Coline CanovasInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR6302, CNRS, University Bourgogne Franche-Comté, Dijon, France.
Victor GoncalvesInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR6302, CNRS, University Bourgogne Franche-Comté, Dijon, France.
Franck DenatInstitut de Chimie Moléculaire de l'Université de Bourgogne, UMR6302, CNRS, University Bourgogne Franche-Comté, Dijon, France.
Philipp T MeyerDepartment of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany.
Helmut R MaeckeDepartment of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany.
University Medical Center Freiburg · DECentre National de la Recherche Scientifique · FRHeidelberg University · DEInstitut de Chimie · FRInstitut de Chimie Moléculaire de l'Université de Bourgogne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe present study aims at developing and evaluating an urea-based prostate specific membrane antigen (PSMA) inhibitor suitable for labeling with 111In for SPECT and intraoperative applications as well as 68Ga and 64Cu for PET imaging.

methodsThe PSMA-based inhibitor-lysine-urea-glutamate-coupled to the spacer Phe-Phe-D-Lys(suberoyl) and functionalized with the enantiomerically pure prochelator (R)-1-(1-carboxy-3-carbotertbutoxypropyl)-4,7-carbotartbutoxymethyl)-1,4,7-triazacyclononane ((R)-NODAGA(tBu)3), to obtain (R)-NODAGA-Phe-Phe-D-Lys(suberoyl)-Lys-urea-Glu (CC34). CC34 was labeled with 111In, 68Ga and 64Cu. The radioconjugates were further evaluated in vitro and in vivo in LNCaP xenografts by biodistribution and PET studies. Biodistribution studies were also performed with 68Ga-HBED-CC-PSMA (HBED-CC: N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid) and 111In-PSMA-617 for comparison.

results68Ga-CC34, 64Cu-CC34, and 111In-CC34 were prepared in radiochemical purity > 95%. 68/natGa-CC34, 64/natCu-CC34, 111/natIn-CC34, 68/natGa-HBED-CC-PSMA, and 111/natIn-PSMA-617 exhibited high affinity for the LNCaP cells, with Kd values of 19.3 ± 2.5 nM, 27.5 ± 2.7 nM, 5.5 ± 0.9 nM, 2.9 ± 0.6 nM and 5.4 ± 0.8 nM, respectively. They revealed comparable internalization profiles with approximately 75% of the total cell associated activity internalized after 3 h of incubation. 68Ga-CC34 showed very high stability after its administration in mice. Tumor uptake of 68Ga-CC34 (14.5 ± 2.9% IA/g) in LNCaP xenografts at 1 h p.i. was comparable to 68Ga-HBED-CC-PSMA (15.8 ± 1.4% IA/g) (P = 0.67). The tumor-to-normal tissue ratios at 1 and 2 h p.i of 68Ga-CC34 were also comparable to 68Ga-HBED-CC-PSMA (P > 0.05). Tumor uptake of 111In-CC34 (28.5 ± 2.6% IA/g) at 1 h p.i. was lower than 111In-PSMA-617 (52.1 ± 6.5% IA/g) (P = 0.02). The acquisition of PET-images with 64Cu-CC34 at later time points showed wash-out from the kidneys, while tumor uptake still remained relatively high. This resulted in an increased tumor-to-kidney ratio over time.

conclusions68Ga-CC34 is comparable to 68Ga-HBED-CC-PSMA in terms of tumor uptake and tumor to normal tissue ratios. 64Cu-CC34 could enable high contrast imaging of PSMA positive tissues characterized by elevated expression of PSMA or when delayed imaging is required. 64Cu-CC34 is currently being prepared for clinical translation.

Indexed as

AcetatesAnimalsAntigens, SurfaceFemaleGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingHumansImage Processing, Computer-AssistedMaleMiceMice, Inbred BALB CPositron-Emission TomographyProstatic NeoplasmsRadiopharmaceuticalsTissue Distribution1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneAcetatesAntigens, SurfaceFOLH1 protein, humanGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingRadiopharmaceuticals

Identifiers

PMID26700033
PMCPMC4689406
OpenAlexW2219927033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.